Clinical Trials Logo

Clinical Trial Summary

Children referred to pediatric urology clinic for primary nocturnal enuresis will be screened for enrollment. Patients who fail will next be offered therapy with a bedwetting alarm device or a TENS unit as an alternative, and those who chose TENS therapy will be included in the study.The patients will be randomized into three groups of 30 patients each. Group 1 will be the long frequency set at 2 Hz (hertz). Group 2 will be the moderate frequency set at 10 Hz. Group 3 will be the short frequency set 150 Hz. The patients will be provided with a TENS unit and electrode pads and caretakers instructed on how to use the apparatus. The child's TENS unit will be set at a frequency determined by randomization, pulse width of 260 seconds, and an intensity to be determined in the office based upon when the child feels sensitive to the TENS unit. The child will be randomized and will place the electrodes along the posterior tibial nerve on the medial ankle each night before bed time for 15 minutes for a total of 30 days. Diaries including nighttime incontinence episodes and a "wet sheet" scale (dry, damp, wet, soaked) will be recorded, along with any adverse reactions to the TENS unit. Patients will be followed up after one month of TENS with evaluation including the Pediatric Urinary Incontinence Questionnaire, a validated tool for measuring quality of life in children with bladder dysfunction; this questionnaire will be filled out prior to starting TENS treatment in order to compare the effect of treatment on QOL. The data will be collected at different time points (baseline and after 1 month of treatment) for each group by itself and the groups compared against each other using statistical analysis.


Clinical Trial Description

Institutional review board approval was obtained. Children ages 5-18 years old referred to the pediatric urology clinic for primary nocturnal enuresis will be screened for enrollment. Behavioral modification (limiting evening drinking, double voiding prior to bedtime, bowel habits, social anxiety factors) will be utilized first. Patients who fail will next be offered therapy with a bedwetting alarm device or a TENS unit as an alternative, and those who chose TENS therapy will be included in the study. Patients who have previously tried pharmacologic treatment for nocturnal enuresis or alternative therapy for urologic disorders within the past 30 days, daytime incontinence symptoms, known "high volume" voiders (determined from history), bedwetting episodes on the average of less than one time per week, medications predisposing to incontinence (eg, Lithium for bipolar disorder), other known voiding or neurologic disorders (eg, overactive bladder, myelomeningocele), secondary etiologies for nocturnal enuresis (eg, cystitis, obstructive sleep apnea, urinary fistulae), prior use of a TENS unit or other neuromodulation for bedwetting, and any contraindications to usage of a TENS unit such as having a pacemaker will be excluded. Patients who have previously tried the bedwetting alarm will not be excluded from the study. The patients will be randomized into three groups of 30 patients each. Group 1 will be the long frequency set at 2 Hz. Group 2 will be the moderate frequency set at 10 Hz. Group 3 will be the short frequency set 150 Hz. There is no sham group in this study as the investigator has previously found posterior tibial TENS to be effective and lasting, and as such all patients will be treated. The investigator will aim to recruit 30 patients per group for a total of 90 patients. Detailed explanation of the purpose if the study, along with the risks and benefits of TENS will be given to the patient and caretakers by a provider prior to obtaining informed consent for enrollment into the study. The patients will be provided with a TENS unit and electrode pads and caretakers instructed on how to use the apparatus. Parents/patients of enrolled patients will fill out nightly voiding diaries, recording nighttime incontinence episodes and subjective "wet sheets" scale per night (dry, damp, wet, soaked) for 30 days prior to randomization into the treatment arms. The TENS sessions will be performed nightly at bedtime for 15 minutes for 30 days. TENS units will be set at a frequency of 10Hz, and intensity determined in the office by the sensitivity threshold of the patient. Voiding diaries will be kept each night while on TENS therapy. A voiding diary will also be completed 30 days before TENS treatment, patients and families will fill out the Pediatric Urinary Incontinence Questionnaire (PIN-Q), a validated tool for measuring quality of life in children with bladder dysfunction. Patients will follow up at day 30 and as needed (worsening symptoms, adverse reactions, concerns, and questions regarding usage of TENS). Patients who record 2 wet nights per week (a total of 8/30=27% wet nights) will be eligible for the TENS study. Those who record less than 2 wet nights per week will be ineligible for the TENS study but will be offered therapy using a bedwetting alarm device or other treatment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04313192
Study type Interventional
Source Albany Medical College
Contact Brenda Romeo, CCRC
Phone 518-262-8579
Email amcurologyreseach@amc.edu
Status Recruiting
Phase N/A
Start date January 20, 2020
Completion date January 1, 2024

See also
  Status Clinical Trial Phase
Completed NCT02600676 - Transcutaneous Electric Nerve Stimulation (TENS) in Children With Enuresis N/A
Completed NCT04191863 - Sleep Architecture in Valproate-induced Nocturnal Enuresis in Primary School and Preschool Children.
Recruiting NCT03199508 - Clinical Values of Voiding Diary for Diagnosis and Treatment for Monosymptomatic Enuresis in Children N/A
Enrolling by invitation NCT05710718 - PureWick™ France and U.S. At-Home Pilot Study N/A
Recruiting NCT06135311 - Optimal Pulse Width Used in Transcutaneous Electrical Nerve Stimulation for Treating Nocturnal Enuresis in Children N/A
Completed NCT03047720 - Scheduled Awakenings for the Treatment of Nocturnal Enuresis N/A
Recruiting NCT05617664 - Mirabegron 25 mg for Treatment of Primary Nocturnal Enuresis N/A
Completed NCT02328092 - A Double-blind Randomized Clinical Trial on the Efficacy of Magnetic Sacral Roots Stimulation for the Treatment of NE N/A
Completed NCT02068560 - The Effect of Gender on Antidiuresis - Evaluated by Graded Low Dose Desmopressin Infusion N/A
Withdrawn NCT02337413 - Urotherapy vs. Urotherapy With Constipation Treatment for Nocturnal Enuresis Phase 4
Completed NCT01368913 - MINRIN® Orally Disintegrating Tablet (Fast Dissolving Desmopressin) and Tablets in Treatment of Primary Nocturnal Enuresis N/A
Terminated NCT04420585 - Desmopressin for Bedwetting in Children With SCD Phase 4
Completed NCT02538302 - Minirin Versus Oxybutynin for Nocturnal Enuresis in Children Phase 3
Recruiting NCT04676139 - The Safety and Efficacy of Fluoxetine for Refractory Primary Mono-symptomatic Nocturnal Enuresis in Children Phase 3
Completed NCT03812094 - Basic Bladder Advice and Alarm Therapy in Nocturnal Enuresis N/A
Recruiting NCT03477812 - Sleep and Nocturnal Enuresis: Ambulatory Polysomnographic Study
Completed NCT02178826 - Nocturnal Enuresis and Rapid Maxillary Expansion N/A
Recruiting NCT01575678 - The Effect of Melatonin on Nocturnal Enuresis Phase 2
Completed NCT01078753 - Study With Two Different Doses of Desmopressin Orally Lyophilisate Tablet With Nocturnal Enuresis Phase 3
Completed NCT05178641 - Overnight Pant Study for Children With Nocturnal Enuresis N/A